LON:FARN Faron Pharmaceuticals Oy (FARN) Share Price, News & Analysis GBX 35.39 +0.39 (+1.11%) As of 09/11/2026 11:25 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider TradesNews and Trends About Faron Pharmaceuticals Oy Stock (LON:FARN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get FARN alerts:Sign Up Key Stats Today's Range 34▼ 3650-Day Range 34.55▼ 4452-Week Range 34▼ 210Volume77,901 shsAverage Volume118,583 shsMarket Capitalization£71.80 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine, the Company's pipeline candidate to prevent vascular leakage and organ failures is currently being tested in several Phase III studies around the world against COVID-19. Traumakine is intravenous IFN beta-1a, which is a strong anti-viral and anti-inflammatory agent. Faron is based in Turku, Finland. Further information is available at www.faron.com Read More Receive FARN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Faron Pharmaceuticals Oy and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FARN Stock News HeadlinesFaron Pharmaceuticals Oy (LON:FARN) Shares Cross Below 50-Day Moving Average - Here's What HappenedSeptember 2, 2026 | americanbankingnews.comFaron Pharmaceuticals Oy: Faron Announces First Patient Enrolled in BEXAR Investigator-Initiated TrialAugust 27, 2026 | finanznachrichten.deGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet production stayed at 5.9 million ounces, unchanged from 2020. Newmont, Barrick and Agnico all face the same reserve shortage, pushing majors toward acquiring smaller producing miners. Recent deals show the pattern: Rupert Resources jumped 67 percent and G2 Goldfields jumped 79 percent the day their buyouts were announced. Analyst Garrett Goggin has identified four junior miners he believes are next on the shopping list.September 12 at 1:00 AM | Golden Portfolio (Ad)Faron Uses Treasury Shares to Settle EUR 1.58m Convertible Bond AmortisationAugust 3, 2026 | tipranks.comFaron posts encouraging survival signal in bexmarilimab HR-MDS trialJuly 27, 2026 | tipranks.comFaron Pharmaceuticals Grants 2.17 Million Share Options Under 2026 Incentive PlanJuly 1, 2026 | tipranks.comFaron Registers New Treasury Shares to Support Potential Bond ConversionsJune 11, 2026 | tipranks.comSeveral Insiders Invested In Faron Pharmaceuticals Oy Flagging Positive NewsJune 5, 2026 | finance.yahoo.comSee More Headlines FARN Stock Analysis - Frequently Asked Questions How have FARN shares performed this year? Faron Pharmaceuticals Oy's stock was trading at GBX 179 at the beginning of the year. Since then, FARN stock has decreased by 80.2% and is now trading at GBX 35.39. How do I buy shares of Faron Pharmaceuticals Oy? Shares of FARN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Faron Pharmaceuticals Oy own? Based on aggregate information from My MarketBeat watchlists, some other companies that Faron Pharmaceuticals Oy investors own include Horizon Discovery Group plc (HZD.L) (HZD), Greencore Group (GNC), Premier African Minerals (PREM), Babcock International Group (BAB), Barclays (BARC), B&M European Value Retail (BME) and Coats Group (COA). Industry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolLON:FARN CIKN/A Webwww.faron.com Phone+358-2-4695151FaxN/AEmployees34Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (11.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£60.23 million Net MarginsN/A Pretax MarginN/A Return on Equity476.49% Return on Assets-70.00% Debt Debt-to-Equity Ratio155.01 Current Ratio2.40 Quick Ratio1.09 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 1.77 per share Price / Cash Flow20.00 Book ValueGBX 1,957.36 per share Price / Book0.02Miscellaneous Outstanding Shares202,881,000Free FloatN/AMarket Cap£71.80 million OptionableNot Optionable Beta1.12 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (LON:FARN) was last updated on 9/12/2026 by MarketBeat.com Staff. From Our PartnersElon Musk to Trigger Next AI Wave on November 11th?Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThis 38 Dollar Fund Holds Every Major AI Stock and Pays WeeklyThe biggest AI stocks like Nvidia, CrowdStrike, and Palantir now trade for hundreds of dollars a share. One fu...Investors Alley | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredThe income “unicorn” Todd Phillips has been waiting 2 years to see againRetirement income specialist Todd Phillips once tracked an unusual income vehicle nicknamed the 10.3 percent U...Eagle Publishing | Sponsoredyour job is on the listThe CEO of one of the largest AI labs on earth said it plainly: AI could wipe out half of all entry-level whit...Behind the Markets | SponsoredWhat Is A Roth Conversion, And How Do I Set One Up?A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...SmartAsset | SponsoredElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Faron Pharmaceuticals Oy Please log in to your account or sign up in order to add this asset to your watchlist. Share Faron Pharmaceuticals Oy With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
